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Pediatric chronic kidney disease (CKD) has peculiar features. In particular, growth impair-
ment  is a major clinical manifestation of CKD that debuts in pediatric age because it presents
in  a large proportion of infants and children with CKD and has a profound impact on the
self-esteem and social integration of the stunted patients. Several factors associated with
CKD  may lead to growth retardation by interfering with the normal physiology of growth
plate,  the organ where longitudinal growth rate takes place. The study of growth plate is
hardly  possible in humans and justiﬁes the use of animal models. Young rats made uremic
by  5/6 nephrectomy have been widely used as a model to investigate growth retardation in
CKD.  This article examines the characteristics of this model and analyzes the utilization of
CKD  induced by high adenine diet as an alternative research protocol.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open  access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Modelos  animales  de  la  enfermedad  renal  crónica  en  edad  pediátrica.  ¿La
ingesta  de  adenina  es  un  modelo  apropiado?
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La enfermedad renal crónica (ERC) tiene características especíﬁcas. De manera especial, el
retraso  del crecimiento es una manifestación clínica importante de la ERC que se inicia en la
infancia  ya que se presenta en un gran número de lactantes y nin˜os con ERC, y repercute pro-
fundamente en la autoestima e integración social de los pacientes afectados. Varios factores
asociados con la ERC pueden provocar retraso del crecimiento por interferencia con la ﬁsi-
ología  normal de la placa de crecimiento, el órgano donde se produce el ritmo de crecimiento
longitudinal. Apenas es posible estudiar la placa de crecimiento en seres humanos y ello
justiﬁca el uso de modelos animales. El modelo más utilizado para investigar el retraso del
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crecimiento en la ERC son ratas jóvenes que se convierten en urémicas por nefrectomía 5/6.
Este  artículo revisa las características de este modelo y analiza el uso de la ERC inducida por
una  dieta con elevado contenido de adenina como protocolo de investigación alternativo.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo  Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Impact  of  chronic  kidney  disease
Chronic kidney disease (CKD) is a global public health prob-
lem because of its associated adverse health outcomes and
high healthcare costs. The Disease Fact Sheet 2014 published
by the Centers for Disease Control and Prevention (CDC), esti-
mates that more  than 10% of adults in USA, which accounts
for more  than 20 million people only in this country, have CKD
with variable disease seriousness. Diabetes and hypertension
are responsible for 7 out of 10 new cases of end stage renal
disease (ESRD) in USA. From 1990 to 2010, deaths from CKD
raised by about 82% worldwide accounting for the third largest
increase among the top 25 causes of death, after acquired
immunodeﬁciency syndrome (396%) and diabetes (93%).1 Car-
diovascular complications are the leading cause of mortality
in adults with CKD so that these patients are more  prone to
die from cardiovascular events than to reach ESRD.
Peculiarities  of  pediatric  chronic  kidney  disease
As adults represent the vast majority of CKD patients, most
publications on CKD focus on adult population. However, CKD
that presents at pediatric age, although less prevalent in abso-
lute terms, has important and distinct peculiarities, as brieﬂy
commented below.
Demography
Whereas the prevalence of CKD in adults is well known, there
are scarce reliable data in children. In North America, 11
cases per million of diagnosed CKD in children between 0 and
19 years have been reported, the prevalence being higher in
males and blacks. In the European Union the incidence stands
around 11–12 cases per million of the age-related population
and the prevalence 56–75 cases per million of the age-related
population, according to several national registries.2,3
Causes
The causes of CKD in pediatric population also differ from
those of adults. Congenital anomalies of the kidney and uri-
nary tract (CAKUT) are the leading cause and account for
approximately 50% of cases. By contrast, acquired glomeru-
lonephritis are the cause of CKD only in 5–14% of children
although this percentage is higher in adolescents and ESRD
cases.4 In European registries, the proportion of CAKUT
(58–59%) was slightly higher, while the proportion of glomeru-
lonephritis was lower (5–7%) than in the NAPRTCS database.5,6
Clinical  manifestations
The key role of interstitial nephropathies as responsible for
pediatric CKD explains that the majority of children who have
CKD, and even ESRD, are polyuric or have preserved diure-
sis, unlike adults. This facilitates the management of these
patients but also entails peculiar therapeutic implications
because of the poorly regulated loss of water and electrolytes,
sodium in particular.It is also of note that CKD is often present
since the ﬁrst months of life and lasts until adulthood.
Although the ﬁnal height of CKD patients has improved
over the last decades,7 the North American Pediatric Trials and
Collaborative Studies (NAPRTCS) 2008 Annual Report showed
that the mean height of 7037 pediatric CKD patients was −1.44
SD score (SDS) and 35% of children had a height below −2 SD.4
Similar data shows the Spanish national registry of children
with CKD (REPIR II), where the mean height of 605 patients was
−1.03 SD and 25% of the children had a height below −1.88 SD8.
On the other hand, a variety of neurocognitive deﬁcits
occur in children with CKD.9 Thus, pediatric CKD has a
profound impact on somatic growth, bone metabolism, and
neurocognitive development.10 The CKD-related effects and
its long-term sequelae are to a large extent different from
those found in adult patients.
Treatment
An adequate metabolic control, optimal nutritional manage-
ment, appropriate hormonal therapy, intensive dialysis and
early renal transplantation are the best remedies to improve
growth and neurological development of children with CKD.11
Animal  models
Animal models have long been used as a research strategy
to increase the knowledge of diseases that affect humans,
particularly to better understand pathophysiological mech-
anisms and to test new therapies. There is wide agreement
that the best experimental models for the study of human dis-
ease should mimic  the entity under consideration in terms of
anatomy, physiology, and course of the disease. Thus, useful
experimental models should facilitate studies both as the dis-
ease evolves and in stable chronic disease. Further, a useful
animal model must adhere to current animal welfare regu-
lations and needs to be technically feasible and ﬁnancially
sustainable. Therefore, it should be reproducible, simple, with
brief experimental time and easy interpretation of the results.
Even if the animal model meets these criteria, it is of note
that ﬁndings derived from animal models must be taken with
 nefrologia. 2 0 1 5;35(6):517–522 519
caution at the moment of establishing a translation of the
results to clinical practice.12
Several types of animal models can be used. Over the last
few decades the use of genetically modiﬁed mice has pro-
gressively increased mostly to ﬁgure out the function of a
gene or a protein and, in turn, to clarify the pathogenesis
and/or the pathophysiological mechanism of a given disease.
Non-genetic models utilize infusions of drugs/substances,
manipulation of diet or environment, or surgical procedures
to induce the target disease. Depending upon the aims of the
intended research, such models may be important and nec-
essary. The use of inbred animals, which has been common
for over 50 years,13 is of special interest to preserve particular
traits and to study a hereditary disease in young animals.
Rats and mice are most frequently used as animal models
of human disease because these species are easy to handle,
relatively cheap and, as a result of their quick life cycle, the
effects of manipulations or therapeutic trials can usually be
appreciated in a short period of time. Moreover, the rodent
animal model is able to reproduce the metabolic disorders
and bone disease that patients with CKD develop during the
clinical course of the disease.14–16
Models  of  CKD
Table 1 shows CKD rat models used to clarify the pathogenesis
and pathophysiology of kidney disease and the response to
several types of therapeutic strategies. Table 1 informs on the
ﬁrst publication describing the model, the latest publication
based on the model at the time of writing this manuscript,
methodology, mechanism by which renal failure is reached
and characteristic features.
This manuscript focuses on the 5/6 nephrectomy uremic
model, because it has been the most widely used to analyze
several aspects of CKD in young rats, particularly those related
with longitudinal growth and bone metabolism, and on the
model of CKD induced by adenine and described in adult rats,
because this model might be useful as animal model of pedi-
atric CKD and presents signiﬁcant advantages on the subtotal
nephrectomy.
The  5/6  nephrectomy  model
Subtotal nephrectomy in two stages, usually 4–7 days apart,
to induce CKD was ﬁrst described by Chanutin and Ferris14 in
1932. In the ﬁrst stage, the upper and lower poles of the left
kidney are functionally suppressed either by surgical scission,
by ligation of the renal artery branches or by electrocauteriza-
tion of renal cortex. In the second stage, the entire right kidney
is removed giving rise to the ﬁnal 5/6 elimination of renal
mass, approximately. After the two stages, animals become
immediately uremic. According to the original description14
urea blood concentration decreases to a constant level dur-
ing the ﬁrst 10 days followed by a gradual increment when
animals initiate polyuria with early dehydration and loss
of weight. Posterior investigations showed loss of weight in
uremic rats compared to sham operated animals.33 In 1974,
Chantler et al.,15 used 5/6 nephrectomy as a model of growth
retardation secondary to CKD and described anorexia as a
characteristic feature of the experimental CKD so that when
glomerular ﬁltration rate drops to below 50% of normal values,
uremic rats eat 30% less than control group. This ﬁnding justi-
ﬁed the need of using sham-operated, normal renal function
rats pair fed with the uremic ones to distinguish between the
effects of uremia per se from those induced by the associated
malnutrition.
The  adenine  model
The deﬁcit of adenine phosphoribosyltransferase is a rare
inherited metabolic disorder that impairs the formation of
2,8-dihydroxyadenine (DHA) in urine.34 Low solubility of DHA
results in recurrent urolithiasis and nephropathy secondary
to crystal precipitation into renal parenchyma.35 Adenine is
more  extensively retained in body tissues than the other
dietary purines orally consumed (guanine, hypoxantine and
xantine).36 High oral administration of adenine is immediately
metabolized to DHA, which precipitates and forms crystals
in the microvilli and the apical epithelial region of the prox-
imal tubule in just 2 days after the adenine intake.37 In
1982, Yokowaza et al.16 proposed a new renal failure model
based on excessive intake of adenine. This model induces
metabolic alterations reproducing CKD characterized by crys-
talline deposits, foreign body granulomas formation in the
renal tubules, and interstitium, and marked ﬁbrosis leading to
tubule-interstitial disease, as usually occurs in many  pediatric
patients with CKD. Moreover, these animals develop hyper-
phosphatemia, secondary hyperparathyroidism, bone mineral
disease, and vascular calciﬁcation.38 Recent data indicate that
some chemokines (CCR5 and CCL3) play an important role
in this CKD model by exacerbating the insult and promoting
ﬁbrosis of the tubule-interstitial lesions.39
Different degrees of uremia can be achieved by varying the
concentration of adenine in diet. Most publications in adult
rats use 0.75% adenine diet to develop this rat model. How-
ever, dietary protocols have not been well established, either
in terms of the adenine concentration in chow, ranging from
0.075 to 0.75%, or the duration of adenine administration, up to
25 weeks.40 Observational periods and therapeutic strategies
have also varied across studies.
The rat’s gender inﬂuences on the response to the adenine
protocol. In 2006, Origima et al.41 concluded that adenine diet
concentration needs to be higher in female rats than in male
rats to induce the same degree of renal failure. Moreover, they
found that male rats fed with adenine diet presented lower
levels of testosterone and reduced bone mineral density than
those receiving normal chow probably because of a mecha-
nism independent of the severity of renal failure. This could
be explained by the fact that adenosine triphosphate and
other nucleotides can stimulate directly the formation and
resorptive activity of osteoclasts, as well as inhibit bone min-
eralization by osteoblasts. Thus, high doses of adenine lead to
an increase in adenosine, which might have direct effects on
the function of osteoblasts and osteoclasts.42 There are no dif-
ferences between both genders with regard to increased blood
pressure, ventricular stiffness or cardiac ﬁbrosis.
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Table 1 – Models of chronic kidney disease (CKD) developed in rats.14,16–32
Initial descriptiona Latest published
referenceb
Procedure Mechanism Distinct features
Lindemann17 Ehrich18 Heterologous
antikidney serum
Nephrotoxin organ speciﬁc -Proper dosage of serum resembles
lipid nephrosis in man
-Evident renal failure  84–313 days
after injection
Schwentker19 Peng20 Injection of bacterial
toxins with
homologous kidney
serum
1.  Induced by Streptococcus,
Staphylococcus, Escherichia
coli or meningococcus
toxines.
2. Development of complex
antikidney-antibodies.
3. Two types of antibodies:
-speciﬁc for kidney
-non-speciﬁc for kidney.
-Clinical and pathological
appearance of acute hemorrhagic
nephritis or cortical necrosis
Vernier21 Petrovic-Djergovic22 Injection of purine 6-Aminonucleoside of
puromycin
-Physiological, biochemical, and
histological changes similar to
those observed in human
nephrotic syndrome
-Chronic administration with
unilateral nephrectomy
reproduces focal sclerosis
Yamamoto23 Chen24 Anti-Thy antibody Polyclonal or a
complement-ﬁxing
monoclonal antibody
directed against the Thy 1
antigen of mesangial cells.
-Mesangyolisis and subsequent
hypercelularity
-Mesangial proliferative nephritis
Mackay25 Muirhead26 Total bilateral
nephrectomy
Nephrectomy in one stage
Nephrectomy in 2 stages
-Rapid  onset of acute renal failure.
Survival about 3–5 days
-Two stage surgery with 7–10 days
of interval
-Survival longer than one stage
nephrectomy
Leconte27 Krim28 Chemical toxins Vinylamine, chromates,
uranium nitrate.
-Achieve chronic nephritis while
coagulated necrosis
-Glomerular and tubular changes
Nagle29 Lopes30 Chronic unilateral
ureteral obstruction
Ureter ligation -Progressive renal ﬁbrosis
-It requires functional suppression
of contralateral kidney
-Possibility of reversing
obstruction
Chanutin14 Tóthová31 5/6 nephrectomy Loss of renal mass -Glomerular sclerosis
Yokowaza16 Yamada32 Oral adenine Crystal deposits in tubular
lumen and interstitium
-Tubule-interstitial nephropathy
a First author and year of publication.
b At the time of writing the manuscript.
The adenine model has been used for testing few treat-
ments. Thus, Ali et al.43 demonstrated in a model of CKD
caused by adenine the usefulness of Gum acacia (a variety
of plant) to treat the anemia of CKD. In a posterior study, and
using a 0.75% adenine model, they reported that gum acacia
improved histological kidney alterations by reducing adenine
deposits and reduced hypertrophy of myocardium.44 Tong
et al.45 demonstrated a slight amelioration of renal function
by administration of Chinese herbs or glibenclamide using a
protocol of rats fed with adenine.
5/6  nephrectomy  vs  adenine  models
Some reports have shown that CKD induced by adenine intake
results in a greater degree and extent of cardiovascular lesions
in the intima-media of the carotid artery than CKD caused by
5/6 nephrectomy, for the same time duration of renal failure.46
Likewise, CKD rats receiving adenine develop signiﬁcant bone
mineral alterations earlier than 5/6 nephrectomized rats.47 In
the adenine model, vascular calciﬁcation and left ventricu-
lar mass increased progressively with the duration of CKD in
association with increased serum ﬁbroblast growth factor 23
(FGF23) and high pulse pressure.48
Ferrari et al.49 recently reported the ﬁrst comparative study
between the adenine and the subtotal nephrectomy mod-
els in a 9 weeks’ protocol. Animals were submitted to a
0.75% adenine diet for the ﬁrst 2 weeks and, subsequently,
to a 0.5% adenine diet. The two groups were comparable in
terms of circulating concentrations of ionized calcium, phos-
phate, parathyroid hormone, and FGF23. Despite the similar
serum phosphate levels, fractional excretion of phosphorus
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Table 2 – Characteristics of rat models of chronic kidney disease CKD induced by subtotal nephrectomy o adenine
intake.14,16,33,37,38,42,46–49
5/6 nephrectomy model Adenine model
Renal manifestations
Intervention Surgery in two stages14 Adenine intake16
Renal damage Loss of renal mass14 Tubulo-interstitial deposit of
2,8-dihydroxyadenine16
Renal failure course Acute renal failure followed by CKD14 Progressive CKD16
Reversible after the ﬁrst four weeks37
Biochemical and clinical characteristics
associated to CKD
Proteinuria, hypertension and cardiac
hypertrophy49
Acidosis, polyuria and hyperphosphaturia49
Kidney histological ﬁndings Progressive glomerular sclerosis49 Tubule-interstitial nephropathy with crystal
precipitation16
Extrarenal manifestations
Bone CKB-BMD49 CKD-BMD. High-turnover bone disease by
possible direct effect of adenine38,42
Heart and vessels Hypertrophy associated with hypertension49 Extensive calciﬁcation of great vessels46,48
Growth Growth retardation and reduction of
endochondral ossiﬁcation at growth plate33
Unknown
Drawbacks and limitations Surgery-related mortality14
Variability in the degree of renal failure14
Irreversibility14
Need to adjust the amount of adenine how to
give and duration48
Long term studies are difﬁcult because
progressive malnutrition and severe CKD47
CKD, chronic kidney disease; CKD-BMD, CKD-bone mineral disorders.
was higher in the adenine group. These animals developed
a more  severe form of bone disease than rats with subtotal
nephrectomy.
It is of note that when the 5/6 nephrectomy is carried out
by excision of one kidney and infarction of the two poles of
the remaining kidney by arterial ligation, there is a marked
increased risk of renovascular hypertension which must be
taken into account at the time of assessing the cardiovascular
effects of this CKD model.50
Table 2 summarizes the main characteristics of 5/6
nephrectomy and adenine models of CKD.
Adenine  model  useful  to  study  pediatric  CKD
The adenine model of CKD is easy to do and reproducible. It
does not require invasive interventions and results in tubule-
interstitial lesions similar to those of CKD that debuts in
infancy and early-childhood. It is associated with the 100%
of animal survival when the adenine diet concentration is
adjusted and the induced CKD may be reversible at not very
high adenine doses. In spite of these characteristics, there are
no published studies of young rats made uremic by adenine
administration.
We propose that administration of adenine to prepuber-
tal rats might be a suitable procedure for the study of CKD in
young individuals. Further studies are needed to characterize
this model in young rats.
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